辛伐他汀干预对急性冠脉综合征患者血清白细胞介素-6、高敏C反应蛋白的影响

目的 探讨辛伐他汀干预对急性冠脉综合征（ACS）患者血清白细胞介素-6（IL-6）和高敏C反应蛋白（hs-CRP）浓度的影响及他汀治疗ACS的机制。方法 分别测定50例ACS、34例稳定型心绞痛（SA）患者及30例正常对照者（NC）血清IL-6、hs-CRP水平；并将ACS组分辛伐他汀组和常规组进行干预，随访3周，再次测定血清IL-6及hs—CRP水平；分析比较组间及辛伐他汀治疗前后血清IL-6及hs—CRP水平。结果 Acs组血清IL-6、hs-CRP水平明显高于SA及NC组（P〈0．001）。干预后，辛伐他汀组血清IL-6、hs—CRP浓度明显下降（P〈0．001）。结论 辛伐他汀具有独立于降脂的抗炎作用，其抗炎作用在ACS患者早期治疗中可能具有重要意义。

Effect of simvastatin upon serum levels of interleukin-6 and high-sensitivity C-reactive protein in patients with acute coronary syndrome

Objective] To explore the effect of simvastatin on serum levels of interleukin-6 and high-sensitivity C-reactive in patients with acute coronary syndrome (ACS) and the mechanism by which statin treat ACS.Method] The serum high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6) levels were measured in 50 patients with ACS, 34 patients with stable angina (SA) and 30 controls. Patients in ACS group were randomly assigned to the simvastatin group (n =25) and the routine group (n =25). The simvastatin group was given simvastatin 20 mg per day and the routine group took placebo. After a three-week follow-up, serum hs-CRP and IL-6 levels were measured again. Results] Both serum IL-6 and hs-CRP levels were significantly higher in ACS group than in SA and Normal Controls (NC) group (P ＜0.001). After three-week treatment with simvastatin, serum IL-6 and hsCRp were decreased significantly in the simvastatin group (P ＜0.001). Conclusion] Simvastatin possess anti-inflammatory effect which independent of its lipid-lowering action, and the anti-inflammatory effect of simvastatin may play an important role in the early treatment of ACS.